Methods of intravenous administration of glyburide
AssigneeBiogen Chesapeake LLC
InventorSven Martin JACOBSON
Life of this patent
Estimating the term…
Abstract
The present disclosure is drawn to a method of treating a patient in need of treatment, comprising identifying a patient in need of treatment for stroke, traumatic brain injury, spinal cord injury, myocardial infarction, shock, organ ischemia, ventricular arrhythmias, ischemic injury, or hypoxia/ischemia; administering a bolus of glyburide to the patient; and administering a continuous infusion of glyburide to the patient at from about 15 μg/hr and about 300 μg/hr, wherein the continuous infusion glyburide is administered for a period of time more than about 20 hours.
Claims21
(canceled)
A method of administering glyburide to a subject, comprising:
- (a) a first bolus administration of glyburide;
- (b) a first continuous infusion administration of glyburide after the first bolus administration of glyburide, wherein the first continuous infusion glyburide is administered at a first rate of administration for a first period of time;
- and
- (c) a second continuous infusion administration of glyburide after the first continuous infusion of glyburide wherein in the second continuous infusion glyburide is administered at a second rate of administration for a second period of time;
- wherein the glyburide is administered to the subject over a period of time, and
- wherein the subject is in need of treatment for stroke, traumatic brain injury, spinal cord injury, myocardial infarction, shock, organ ischemia, ventricular arrhythmias, ischemic injury, or hypoxia/ischemia.
Dependencies are inferred from the claim text.